Imaging of Cancer via Intraoperative Coded Aperture Radioscintigraphy (BIDMC 717)

Category:    Medical Imaging

KeyWords:  Cancer;  Cancer;  Surgery;  

BIDMC ID:    717

Abstract:

Background: Oncologic surgery requires identification and removal of all malignant cells. Detection and removal of entire malignant cells population is crucial for complete recovery of the patient. According to the American cancer society, about 1,368,030 new cancer cases are expected to be diagnosed in 2004, and about 563,700 Americans are expected to die of cancer in 2004. Cancer is the second leading cause of death in the US, exceeded only by heart disease. Oncologic surgery is greatly complicated when cells escape the primary site of surgery, and yet with the right imaging technology these cells could be detected and removed. Invention: This invention is an improvement to the sensitivity of the inventor?s Intraoperative imaging system for near-infrared fluorescence technology, subject of patent application PCT/US03/29368 ?medical imaging systems?, that permits real-time detection of malignant cells within the surgical field using light. This invention improves the imaging system by several orders of magnitude using radiosintigraphic detection of malignant cells and FDA approved tumor-specific radiologics.

Inventor:   John V. Frangioni, M.D., Ph.D., Richard C.Lanza, Ph.D., Robert Accorsi, Ph.D. and John Idoine, Ph.D.

Commercial Opportunity:

According to U.S. Department of Energy (DOE), isotope sales for nuclear medicine procedures total more than $100 million each year. This invention is applicable for oncologic surgery in conjunction with commercially available radiolabled, tumor-localizing antibodies or FDA approved PET agents.

Competitive Advantages:

? Unlike conventional collimated gamma cameras, coded aperture imaging provides tomographic depth information that can lead to a better and more precise localization of the tumor (443-fold increased sensitivity) ? The merge of color video and radioscintigraphic information provides the surgeon withan unparalleled ability to identify and remove cancerous tissue. ? This method enables the detection of extremely small volumes of metastatic cells.

Related Publications:

*An operational near-infrared fluorescence imaging system prototype for large animal surgery. De Grand AM, Frangioni JV. Technol Cancer Res Treat. 2003 Dec;2(6):553-62
*In vivo near-infrared fluorescence imaging. Frangioni JV. Curr Opin Chem Biol. 2003 Oct;7(5):626-34.
* IRDye78 conjugates for near-infrared fluorescence imaging. Zaheer A, Wheat TE, Frangioni JV.Mol Imaging. 2002 Oct;1(4):354-64.

State of Development:

Related Technology URL:

http://research.bidmc.harvard.edu/research/ResearchPIInfo.ASP?Submit=Display&PersonID=206

Patent Status:

US provisional pending

TVO Contact Info:
     Jason S Felsch
     Senior Licensing Manager, TVO
     jfelsch@bidmc.harvard.edu
     Phone: 617-667-9490   Fax: 617-667-0646

     Beth Israel Deaconess Medical Center
     Technology Ventures Office  Room: BR-202
     330 Brookline Avenue
     Boston, MA 02215